First conjugates based on a Sigma receptor modulator and a proteasome-impairing agent. Design, synthesis and exploratory biological evaluation in cancer cells.
Abstract
Cancer cells rely on a finely tuned proteostasis network to cope with high metabolic and proliferative demands. Targeting this vulnerability through the simultaneous modulation of both Sigma receptors (SRs) subtypes (i.e. S1R and S2R) and proteasome function represents an attractive and unprecedented strategy for the development of potential anti-cancer agents. The connection between Sigma receptor signalling and proteostasis suggested the design of conjugates combining a SRs modulator scaffold with a scaffold able to reduce proteasomal activity in cells. Here, we report the design, synthesis and exploratory biological evaluation of four conjugates (15a-b and 16a-b) obtained by linking RC-106 and IP24 through PEG-based spacers, varying the attachment site on the RC-106 scaffold and the linker length. These prototypes retained SRs affinity, with the site of derivatization on the RC-106 scaffold dictating subtype preference. In glioblastoma (GBM) cell lines (T98G and U87-MG) and multiple myeloma (MM) cell lines (RPMI-8226) the new compounds were markedly more effective than the parent compounds. The most potent analogue, 16a (RC-241), showed an IC50 of 1.66 μM in T98G cells after 72 h and retained activity in 3D U87-MG spheroids. The compounds did not inhibit the isolated 20S proteasome, yet induced dose-dependent proteasome impairment in intact cells, pointing to an indirect, cell-context dependent mechanism. Holotomographic live-cell imaging in T98G cells showed that RC-241 triggers cytoplasmic vacuolization and accumulation of misfolded proteins, a morphology consistent with paraptosis-like death driven by unresolved proteotoxic stress. These results provide the first experimental assessment of the in vitro anticancer activity of conjugates designed to combine SRs modulation with proteasome impairment, and identify RC-241 as a starting point for further investigation of proteostasis-directed strategies in GBM and MM.